-
公开(公告)号:US20210207146A1
公开(公告)日:2021-07-08
申请号:US16984887
申请日:2020-08-04
发明人: Thazha P. Prakash , Punit P. Seth , Eric E. Swayze , Sanjay Bhanot , Susan M. Freier , Huynh-Hoa Bui
IPC分类号: C12N15/113
摘要: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with excess growth hormone using antisense compounds or oligonucleotides targeted to growth hormone receptor (GHR).
-
公开(公告)号:US20190071677A1
公开(公告)日:2019-03-07
申请号:US16057471
申请日:2018-08-07
发明人: Susan M. FREIER , Rosanne M. Crooke , Mark J. Graham , Kristina M. Lemonidis , Diane Tribble , Sanjay Bhanot , Andrew T. Watt
IPC分类号: C12N15/113 , A61K45/06
摘要: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
-
公开(公告)号:US20170166899A1
公开(公告)日:2017-06-15
申请号:US15307990
申请日:2015-05-01
发明人: Thazha P. Prakash , Punit P. Seth , Eric E. Swayze , Sanjay Bhanot , Susan M. Freier , Huynh-Hoa Bui
IPC分类号: C12N15/113
CPC分类号: C12N15/1138 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3231 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12N2310/351 , C12N2310/3525
摘要: The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating a disease associated with excess growth hormone using antisense compounds oligonucleotides targeted to growth hormone receptor (GHR).
-
公开(公告)号:US11530410B2
公开(公告)日:2022-12-20
申请号:US17032550
申请日:2020-09-25
发明人: Susan M. Freier , Rosanne M. Crooke , Mark J. Graham , Kristina M. Lemonidis , Diane Tribble , Sanjay Bhanot , Andrew T. Watt
IPC分类号: C12N15/113 , A61K45/06 , A61K48/00
摘要: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
-
公开(公告)号:US10793862B2
公开(公告)日:2020-10-06
申请号:US16521344
申请日:2019-07-24
发明人: Thazha P. Prakash , Punit P. Seth , Eric E. Swayze , Sanjay Bhanot , Susan M. Freier , Huynh-Hoa Bui
IPC分类号: C12N15/113 , C07H21/02
摘要: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with excess growth hormone using antisense compounds or oligonucleotides targeted to growth hormone receptor (GHR).
-
公开(公告)号:US20200123551A1
公开(公告)日:2020-04-23
申请号:US16521344
申请日:2019-07-24
发明人: Thazha P. Prakash , Punit P. Seth , Eric E. Swayze , Sanjay Bhanot , Susan M. Freier , Huynh-Hoa Bui
IPC分类号: C12N15/113
摘要: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with excess growth hormone using antisense compounds or oligonucleotides targeted to growth hormone receptor (GHR).
-
公开(公告)号:US20200040341A1
公开(公告)日:2020-02-06
申请号:US16456432
申请日:2019-06-28
发明人: Sanjay Bhanot , Susan M. Freier , Eric E. Swayze
IPC分类号: C12N15/113 , C07H21/00 , A61P1/16
摘要: The present embodiments provide methods, compounds, and compositions useful for inhibiting DGAT2 expression, which may be useful for treating, preventing, or ameliorating a disease associated with DGAT2.
-
公开(公告)号:US20230137382A1
公开(公告)日:2023-05-04
申请号:US17987064
申请日:2022-11-15
发明人: Susan M. Freier , Rosanne M. Crooke , Mark J. Graham , Kristina M. Lemonidis , Diane Tribble , Sanjay Bhanot , Andrew T. Watt
IPC分类号: C12N15/113 , A61K45/06
摘要: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
-
公开(公告)号:US20230047452A1
公开(公告)日:2023-02-16
申请号:US17677875
申请日:2022-02-22
发明人: Sanjay Bhanot , Susan M. Freier , Eric E. Swayze
IPC分类号: C12N15/113 , C07H21/00 , A61P1/16
摘要: The present embodiments provide methods, compounds, and compositions useful for inhibiting DGAT2 expression, which may be useful for treating, preventing, or ameliorating a disease associated with DGAT2.
-
公开(公告)号:US09617540B2
公开(公告)日:2017-04-11
申请号:US14698554
申请日:2015-04-28
发明人: Sanjay Bhanot , Richard S. Geary , Robert McKay , Brett P. Monia , Punit P. Seth , Andrew M. Siwkowski , Eric E. Swayze , Edward Wancewicz
IPC分类号: C12N15/113
CPC分类号: C12N15/113 , C12N15/1137 , C12N2310/11 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/341 , C12N2310/3515 , C12Y203/0102 , C12N2310/3521
摘要: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
-
-
-
-
-
-
-
-
-